Shanghai Bao Pharmaceuticals Co., Ltd. (02659.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.45B

MomentumView details →

1D Return

−2.25%

YTD Return

−79.29%

RSI (14)

39.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.45B

RSI (14)

39.2

MomentumView details →

1D Return

−2.25%

YTD Return

−79.29%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.07

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 26, 2027 →

Latest newsMore news →

Shanghai Baoye Pharmaceutical reported interim results for the six months ended June 2026, with revenue down 76.5% year-on-year to RMB 9.875 million and a narrowed net loss of RMB 154 million.7d ago

Similar companies

Trevi Therapeutics, Inc.TRVI Harmony Biosciences Holdings, Inc.HRMY Pharvaris N.V.PHVS Mineralys Therapeutics, Inc.MLYS Nuvation Bio Inc.NUVB Sarepta Therapeutics, Inc.SRPT Find similar companies →

Latest newsMore news →

Shanghai Baoye Pharmaceutical reported interim results for the six months ended June 2026, with revenue down 76.5% year-on-year to RMB 9.875 million and a narrowed net loss of RMB 154 million.7d ago